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Retrovirus entryThree N-linked glycosylation sites were removed from the envelope glycoproteins of Friend, Moloney, and
AKV mouse ecotropic gammaretroviruses: gs1 and gs2, in the receptor binding domain; and gs8, in a region
implicated in post-binding cell fusion. Mutants were tested for their ability to infect rodent cells expressing 4
CAT-1 receptor variants. Three mutants (Mo-gs1, Mo-gs2, and Fr-gs1) infect NIH 3T3 and rat XC cells, but are
severely restricted inMus dunni cells and Lec8, a Chinese hamster cell line susceptible to ecotropic virus. This
restriction is reproduced in ferret cells expressing M. dunni dCAT-1, but not in cells expressing NIH 3T3
mCAT-1. Virus binding assays, pseudotype assays, and the use of glycosylation inhibitors further suggest that
restriction is primarily due to receptor polymorphism and, in M. dunni cells, to glycosylation of cellular
proteins. Virus envelope glycan size or type does not affect infectivity. Thus, host range variation due to N-
glycan deletion is receptor variant-speciﬁc, cell-speciﬁc, virus type-speciﬁc, and glycan site-speciﬁc.
Published by Elsevier Inc.Introduction
The initial event in the process of gammaretrovirus entry is the
interaction between the viral envelope (Env) glycoprotein and its
cellular receptor. For the mouse leukemia virus (MLV) gammaretro-
viruses, there are multiple host range variants that are determined by
sequence variation in the receptor binding domain (RBD) of the Env
SU (surface) component. Each host range group utilizes a different
receptor, all of which are transporter proteins with multiple
transmembrane domains (Tailor et al., 2003; Stocking and Kozak,
2008). Receptor binding of the RBD triggers a conformational change
in Env that results in exposure of the fusion domain of the Env TM
(transmembrane) component that then initiates the fusion of viral
and cellular membranes.
The viral Envs as well as their cell surface receptors are modiﬁed
post-translationally by glycosylation. These glycoproteins acquire N-
linked oligosaccharides that are initially transferred to nascent
polypeptide chains in the ER from a dolichol precursor. These glycans
are subsequently modiﬁed by glycosidases and glycosyl transferases
as the proteins are transported through the Golgi.
The CAT-1 receptor for the ecotropic host range subgroup of MLVs
(E-MLVs) carries two consensus recognition sites for N-linkedoom 329, 4 Center Drive MSC
6477.
Inc.glycosylation (N-X-S/T, where X is any amino acid except P). These
glycosylation sites are both occupied by N-glycans (Kim and Cunning-
ham, 1993). Both sites are found in the 3rd extracellular loop which
also carries the amino acid residues critical for receptor function
(Albritton et al., 1993; Yoshimoto et al., 1993). CAT-1 receptors from
which N-glycans have been removed by mutagenesis continue to
mediate virus entry, and there is some indication that deglycosylated
CAT-1 is a more efﬁcient receptor (Wang et al., 1996). Glycosylation is
also associated with a number of receptor-mediated resistance
phenotypes that have been identiﬁed for speciﬁc virus–host combina-
tions. These restrictions include the restriction of MoMLV by Mus
dunni cells (Eiden et al., 1993, 1994), restriction of E-MLVs by Chinese
hamster and rat cells (Miller and Miller, 1992, 1993; Tavoloni and
Rudenholz, 1997), and restriction of the MoMLV variant Spl574 by
laboratory mouse cells (Yan et al., 2008). All of these restrictions are
relieved by inhibitors of glycosylation.
The viral Env glycoprotein is also glycosylated. E-MLV Env has a
small number of glycans compared to more complex retroviruses like
HIV-1; MLVs have 7–9 N-glycans, and one site for O-linked glycosyla-
tion (Pinter and Honnen, 1988). Four N-glycan sites, gs3, 5, 7, and 8,
are variably present. One N-glycan site, gs2, uniquely carries an
endoglycosidase H-sensitive high-mannose glycan; the others carry
complex types (Kayman et al., 1991). The use of inhibitors to block N-
linked glycosylation during virus replication has demonstrated that
glycans are critical for the maturation and transport of Env. Inhibitors
that speciﬁcally block the earliest steps in glycosylation can prevent
cleavage of the Env precursor into SU and TM resulting in virions with
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data on the possible functional roles of the individual Env N-glycans.
Felkner and Roth (1992) showed that loss of MoMLV gs2 resulted in
temperature sensitive production of virus in Rat2 cells, and loss of gs4
from MoMLV and FrMLV produced noninfectious virus lacking SU
protein; the gs4 mutation inhibited processing and prevented
incorporation of Env into virus, although it was also shown that a
glycan at this site is not required for Env function (Felkner and Roth,
1992; Kayman et al., 1991; Li et al., 1997).
In this study we assess the entry properties of 3 different E-MLV
isolates mutagenized to eliminate one of three N-glycan sites: gs1 and
gs2, the two glycan sites in the RBD, and gs8, located in a region of the
C-terminal domain of SU known to mediate post-receptor binding
fusion (Burkhart et al., 2005). We characterize these viruses for their
ability to mediate binding and entry with 4 naturally occurring CAT-1
variants found in different rodent species.
Results
Altered host range of viruses lacking speciﬁc N-glycan sites
We used site-speciﬁc mutagenesis to remove individually one of
three sites for N-linked glycosylation from three E-MLVs: MoMLV,
FrMLV, and AKV MLV (Fig. 1A). Two sites (gs1, gs2) are located in
the 236 amino acid receptor binding domain (RBD) for all threeFig. 1. N-linked glycosylation in Env of 3 ecotropic gammaretroviruses (A) Location of N-glyca
that lack gs1, gs2 or gs8 as indicated. The domain structure of Env is indicated at the top. RBD
rich domain; LS: leader sequence. (B) Western immunoblot analysis of protein lysates from v
left and top right were reacted with goat anti-gp70; the panel in the lower right was reacteviruses, whereas a third site, gs8, is found in MoMLV and FrMLV but
not AKV MLV. This third site maps to a region that has been
implicated in post-binding cell fusion (Burkhart et al., 2005), and
provides the epitope for the GIX cell surface marker (Rosner et al.,
1980). Single glycosylation site mutants were generated for all 3
sites in MoMLV, for the two RBD sites in AKV MLV, and gs1 was
removed from FrMLV.
Western analysis of virus-infected NIH 3T3 cells with anti-gp70
shows that, as expected, removal of these sites reduces the size of the
Env precursor, gPr80Env, as well as the size of the processed SU for all
6 mutants (Fig. 1B). We also used the MoMLV Env-speciﬁc antibody
MAb538 to analyze the three MoMLV mutants; MAb538 reacts with
gPr80Env but not SU on western blots. MAb538 detects MoMLV and
Mo-gs2, but notMo-gs1 orMo-gs8 (Fig.1B), indicating that removal of
individual glycosylation sites alters the immunogenicity of this
glycoprotein.
We tested the mutant viruses for infectivity on cells of 2 Mus
species and 2 non-Mus rodent species with functional, but variant
CAT-1 receptors. These 4 receptors differ in their third extracellular
loop that carries critical residues for entry (Fig. 2A). dCAT-1 from the
Asian M. dunni mouse differs from laboratory mouse mCAT-1 at two
sites in this loop. The hamster choCAT-1 and rat xcCAT-1 genes have
several substitutions relative to mCAT-1 and have additional residues
ﬂanking one of the two glycosylation sites in this loop; rat xcCAT-1
also lacks one of the 2 glycosylation sites (Kubo et al., 2002). Chinesen sites in the Env genes of MoMLV, FrMLV57 and AKVMLV. Six mutants were generated
: receptor binding domain; VRA, VRC and VRB: variable regions A, C and B; PRD: proline-
irus-infected cells. NIH 3T3 cells were infected with the indicated viruses. Panels at the
d with MoMLV speciﬁc MAb538.
Fig. 2. Infectivity of wild type ecotropic MLVs and mutated viruses that lack speciﬁc sites for N-glycans. A) Amino acid sequence comparisons of rodent variants of the third
extracellular loop of the CAT-1 receptor. mCAT-1 is found in laboratory mouse strains and dCAT-1 is found in the Asian wild mouse species M. terricolor (M. dunni). choCAT-1 and
xcCAT-1 are the Chinese hamster and rat XC cell variants. Sites for N-glycosylation are shaded. Glycosylation sites were removed from dCAT-1 to produce dCAT-1-g as described
previously (Yan et al., 2008). References or GenBank accession nos. are provided for each sequence. B) Viruses were tested on 5 cell lines carrying 4 naturally occurring variants of the
CAT-1 receptor. Virus titers were determined by the XC overlay test in which the indicated cells were infected with virus dilutions, irradiated and overlaid with XC cells to identify
virus infected cells (Rowe et al., 1970; Yan et al., 2008). Virus titers are given as the log10 number of XC PFU in 0.2 ml. Chinese hamster E36 cells were resistant to infection by all
viruses (not shown). Results represent means+/− SD of at least 4 determinations. Each set of viruses was from one representative experiment; each set was tested at least 3 times.
SD of the data are also shown. Arrow: in 8 trials, XC plaques were produced once for the two viruses, with log10 virus titers of 0.2 for Mo-gs1 and 0.3 for Mo-gs2. X: not done.
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but this restriction is mediated by glycosylation (Miller and Miller,
1992) and is relieved in Chinese hamster Lec8 cells (Miller and Miller,
1993), a line that lacks GlcNAc-transferase I (Gottlieb et al., 1975), an
enzyme involved in N-glycan processing.
Susceptibility to 3 ecotropic MLVs and glycosylation mutants was
assessed by the XC overlay test (Fig. 2B). MoMLV is restricted in both
of the M. dunni-derived cell lines used here; these lines were derived
from tail cells cultured from a single mouse (Lander and Chattopad-
hyay, 1984), but cells were subsequently distributed to different
laboratories and now differ in the extent of their resistance to MoMLV.
Removal of the gs8 site fromMoMLV had no clear effect on the ability
of this MoMLV derivative to infect cells carrying mCAT-1, dCAT-1 or
choCAT-1. Removal of gs1 and gs2, however, produced viruses that
efﬁciently infected NIH 3T3 cells and XC cells, but were substantially
less infectious for M. dunni, MDTF and Lec8 cells than wild type
MoMLV. On M. dunni cells, no XC plaques were produced by either
Mo-gs1 or Mo-gs2 in 7 of 8 tests, a million-fold reduction compared to
the infectivity of these viruses on NIH 3T3, and a reduction of over
100-fold relative to the infectivity of MoMLV in these same cells. We
also tested these viruses onMDTF cells, which are more sensitive than
M. dunni cells to MoMLV (Fig. 2B); replication of the MoMLV mutantswas detected, but was reduced at least 1000-fold compared to wild
type MoMLV.
AKV MLV and FrMLV57 show small differences in infectivity for
NIH 3T3 and M. dunni mouse cells (Fig. 2B). Removal of either gs1 or
gs2 from AKV MLV produced viruses showing no differences in
infectivity on these cells. However, as was seen for Mo-gs1, Fr-gs1 was
substantially less infectious thanwild type FrMLV57 forM. dunni cells;
this is also consistent with a previous observation that removal of both
RBD glycan sites from FrMLV results in reduced infectivity onM. dunni
cells (Battini et al., 1994). These results taken together indicate that
removal of speciﬁc N-glycan sites from the MLV envelope can produce
detectable changes in immunogenicity, and that glycans in the RBDs of
MoMLV and FrMLV, but not AKV MLV, are needed for efﬁcient entry
into cells with 2 of the receptor variants tested here, dCAT-1 and
choCAT-1.
Infectivity of viruses with altered N-glycans
To determine if the viruses that showed altered infectivity after
removal of speciﬁc N-glycan sites would also show altered
infectivity if Env N-oligosaccharides were modiﬁed by type or size,
we used two methods to generate viruses with altered glycans. First,
Fig. 3.Western immunoblot analysis of lysates fromMoMLV-infected cells. (A) NIH 3T3
(N) or hamster Lec8 (L) cells infected with MoMLV or FrMLV and probed with goat anti-
gp70. (B) Cell lysates from NIH 3T3 cells treated with the indicated inhibitors. After the
reaction with MAb538 (on the bottom), the ﬁlter was stripped and probed with anti-
gp70. Lanes separated by a space were from the same exposure of a single ﬁlter.
Fig. 4. Virus titers of ecotropic MLVs on mouse cells and on mouse and ferret
transfectants expressing speciﬁc CAT-1 receptors. Virus titers were measured as the
number of XC PFU in 0.2 ml using the XC overlay test. Results represent means+/−SD
from at least 3 determinations are from a representative experiment. SD of the data are
also shown. Arrow: no XC plaques detected in 5 trials. X, not done.
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GlcNAc-transferase I, Lec8 cell glycoproteins carry smaller Man5
(GlcNAc)2-oligosaccharides and the SU glycoproteins produced in
these Lec8 cells are markedly reduced in size (Fig. 3A). Second, we
treated MLV infected cells with 4 inhibitors of glycosylation to
produce viruses with other types of altered N-glycans (Fig. 3B). The
inhibitors speciﬁcally block different enzymes involved in N-
glycosylation: CST blocks glucosidase I and generates immature
Glc3Man7–9 oligosaccharides; DNM blocks glucosidase II and
produces Glc1–2Man7–9 structures; DMM blocks mannosidase I and
produces Man7–9(GlcNAc)2 structures that lack glucose. All three of
these inhibitors thus produce high-mannose structures. Sw blocks
mannosidase II and inhibits formation of N-linked complex
oligosaccharides, so hybrid structures are produced (Man4GlcNAc2,
Man5GlcNAc2, hybrid chains). Western analysis indicates that the
early glycosylation blocks by CST or DNM treatment increase the
size of gPr80env and reduce processing into SU. SU produced in the
presence of DMM, DNM and Sw is decreased in size (Fig. 3B).
gPr80Envs produced in the presence of the various inhibitors are all
identiﬁed by MAb538 by Western immunoblotting, except for the
CST-modiﬁed glycoprotein (Fig. 3B).
FrMLV andMoMLV stocks produced in Lec8 cells or in the presence
of DMM, DNM and Sw were tested for relative infectivity on M. dunni
and NIH 3T3 cells. All stocks tested contained infectious virus. All of
the FrMLVs showed comparable infectivity on the two cells by the XC
overlay test (data not shown). All of the MoMLVs showed greater
infectivity on NIH 3T3 cells compared to M. dunni, within the range
typically observed for MoMLV (data not shown). This suggests that
Env glycan type or size does not inﬂuence receptor usage of E-MLVs.
Infectivity on stable transfectants expressing different Mus CAT-1
receptor genes
To determine if the observed differences in infectivity with the
deglycosylated viruses could be attributed to the CAT-1 receptor
variants in these cells, the viruses were used to infect stable
transfectants expressing dCAT-1 or mCAT-1 (Fig. 4). M. dunni cells
expressing mCAT-1 in addition to endogenous dCAT-1 showedincreased infectibility with MoMLV but infectibility of these cells
with FrMLV was not altered, as previously shown (Yan et al., 2008).
These cells also showed increased infectibility with Mo-gs1, Mo-gs2,
and Fr-gs1. Thus, the expression of mCAT-1 in M. dunni cells resulted
in virus-speciﬁc increased susceptibility to Fr-gs1 and to the 3 MoMLV
variants.
Expression of mCAT-1 or dCAT-1 in MA139 ferret cells renders
them susceptible to E-MLV infection (Yan et al., 2008) (Fig. 4). As
previously noted, ferret cells expressing mCAT-1 (FerrM) and dCAT-1
(FerrD) are equally infectible by MoMLV indicating that the sequence
difference between mCAT-1 and dCAT-1 does not account for the
MoMLV susceptibility difference between NIH 3T3 and M. dunni cells
(Yan et al., 2008). However, while FerrM was equivalently susceptible
to MoMLV, Mo-gs1 and Mo-gs2, FerrD was nearly 1000-fold less
susceptible to Mo-gs1 and Mo-gs2. We also infected a ferret
transfectant expressing dCAT-1 from which the two N-glycan sites
had been deleted by mutagenesis (Fig. 2A) (Yan et al., 2008). The cells
expressing deglycosylated dCAT-1-g showed the same pattern of virus
susceptibility as FerrD (data not shown).
These same ferret transfectants were infected with FrMLV and
Fr-gs1. Fr-gs1, like Mo-gs1, showed reduced infectivity in the
transfectants expressing dCAT-1 (Fig. 4) and dCAT-1-g (data not
shown) compared to the mCAT-1 transfectant. These results
indicate that while the CAT-1 sequence difference does not account
for the resistance of M. dunni to MoMLV, this sequence difference
is an important factor that inﬂuences susceptibility to the
deglycosylated viruses. Removal of gs1 from FrMLV and either
RBD glycan from MoMLV compromises the ability of these MLVs to
interact with the dCAT-1 receptor, but not with the mCAT-1
Table 1
Effect of various glycosylation inhibitors on the ability of MoMLV and FrMLV wild type
virus and glycosylation mutants to replicate in M. dunni cells.
Virus Log10 virus titer with glycosylation inhibitorsa
– Tu 2DG DMM CST Sw
MoMLV 2.4 5.0 4.8 4.4 4.1 4.8
Mo-gs1 — 1.0 2.1 0.6 0.9 0.9
Mo-gs2 — 1.3 2.9 2.1 1.5 1.5
FrMLV57 4.6 ND 4.5 4.4 4.4 4.6
Fr-gs1 1.6 ND 3.3 2.9 2.6 2.6
a Virus was quantitated using the XC overlay assay and numbers represent XC PFU in
0.2 ml. Glycosylation inhibitors were added the day before virus infection. Each virus–
inhibitor combination was tested three times; the numbers represent a representative
experiment.—, no positive cells in cultures infected with 0.1 ml of undiluted virus stock.
ND, not done.
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of heterologous species.
Effect of glycosylation inhibitors on virus infectivity
The reduction in susceptibility to deglycosylated MoMLV and
FrMLV in dCAT-1 versus mCAT-1 expressing ferret cells is not as
dramatic as the susceptibility differences between M. dunni and NIH
3T3. This suggests that other factors may contribute to the
resistance of M. dunni cells. Because glycosylation contributes to
MoMLV resistance in dunni cells (Eiden et al., 1994; Yan et al.,
2008), we tested the effects of inhibitors of glycosylation on
infectivity of deglycosylated viruses in M. dunni cells (Table 1). All
inhibitors tested increased susceptibility to MoMLV as well as to
Mo-gs1, Mo-gs2, and Fr-gs1, but not to FrMLV57. Thus, glycosylation
is a contributing factor to restriction of Fr-gs1 and all of the MoMLV
variants in M. dunni cells.
Pseudotype infections
To determine if removal of envelope glycans affects later stages in
the viral life cycle, we infected cells with pseudotypes carrying the
LacZ reporter gene. Pseudotypeswere generated for MoMLV, FrMLV57,
and their respective gs1 mutants.
As observed previously, the MoMLV pseudotype is restricted in M.
dunni cells although these cells are susceptible to infection with the
FrMLV57 pseudotype (Table 2) (Yan et al., 2008). M. dunni cells
showed no detectable infection with pseudotypes of either Mo-gs1 or
Fr-gs1, consistent with the XC overlay test results (Fig. 2B).
The transfected MA139 line carrying mCAT-1, FerrM, was efﬁ-
ciently infected by all 4 pseudotypes as also shown by the XC test (Fig.
4). In contrast, FerrD cells expressing dCAT-1 resemble FerrM in their
susceptibility to FrMLV and MoMLV pseudotypes, but show a 60–100-
fold reduction in sensitivity to pseudotypes of both gs1mutants (Table
2). These results are consistent with the XC test results and indicate
that the restriction of viruses lacking speciﬁc glycans is receptor-
mediated.Table 2
Titers of ecotropic LacZ virus pseudotypes in mouse cells and MA139 cells transfected
with mCAT-1 (FerrM) or dCAT-1 (FerrD).
Cellsb Log10 titer of LacZ pseudotypesa
MoMLV Mo-gs1 FrMLV57 Fr-gs1
NIH 3T3 4.3 4.4 4.1 4.7
M. dunni — — 3.4 —
FerrM (mCAT-1) 3.5 3.6 3.5 4.0
FerrD (dCAT-1) 2.9 1.5 3.5 2.3
—, no positive cells in cultures infected with 0.1 ml of undiluted pseudotype stock.
Experiment was done twice; numbers represent results from one experiment.
a Measured as thenumber of cells positive forβ-galactosidase activity in 100 μl of virus.
b CAT-1 gene expressed in transfected cells is given in ().Virus binding assays
To determine if the removal of glycans affects virus binding to the
CAT-1 receptor or a later stage in the entry process, we performed
virus binding assays on NIH 3T3, M. dunni and MDTF cells with
MoMLV, FrMLV57, and their respective gs1 glycosylation mutants. We
also used the ferret transfectants FerrM and FerrD to evaluate binding
of FrMLV57 and Fr-gs1.
Binding of each virus was initially assessed on NIH 3T3 cells (Figs.
5A, B). Strong virus binding was observed on NIH 3T3 cells for both
wild type viruses, and removal of glycosylation sites only slightly
modulated the virus binding characteristics in a virus-speciﬁc manner.
Mo-gs1 had a slightly decreased binding efﬁcacy compared to MoMLV
(Fig. 5A) whereas Fr-gs1 showed slightly increased binding (Fig. 5B),
reﬂecting the different XC plaque titers produced by these virus stocks
on NIH 3T3 (Fig. 2B).
Virus binding properties were drastically different on M. dunni
(data not shown) and MDTF cells (Figs. 5C, D), which showed nearly
identical properties. Binding of MoMLV and Mo-gs1 were undetect-
able on M. dunni and MDTF cells (Fig. 5C), consistent with the poor
infectivity of both viruses on these cells. Binding of FrMLV57 was
detected on both dunni cell lines but was reduced compared to NIHFig. 5. Virus binding assay performed on NIH3T3 (A, B), MDTF (C, D) FerrM (E) and
FerrD (F) cells. Dead cells were excluded by gating 7-AAD negative cells. Viruses used in
these experiments included Mo-MuLV (black line, panel A and C) and its Mo-gs1
glycosylation mutant (broken line, panel A and C) and Friend MuLV (black line, panel B,
D–F) and its Fr-gs1 glycosylation mutant (broken line, panel B, D, E and F). Cells treated
similarly in absence of virus suspension served as negative control (grey histogram in
all panels).
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this virus which was 5–10-fold higher on M. dunni than on NIH 3T3
cells suggesting that other cell-speciﬁc factors may inﬂuence virus
replication. In contrast to wild type FrMLV57, Fr-gs1 had no detectable
binding ability on either M. dunni or MDTF cells (Fig. 5D). These data
suggest that removal of gs1 from FrMLV57, a virus capable of infecting
M. dunni cells, drastically reduces its ability to recognize the dCAT-1
receptor, preventing efﬁcient replication on these cells.
Virusbindingof FrMLV57andFr-gs1was alsoassessedonFerrMand
FerrB cells. Both viruses showed reduced but equivalent binding to
FerrMcells (Fig. 5E), consistentwith theobservation that these cells are
less susceptible to MLVs than mouse cells (Fig. 4). FerrD resembled
FerrM in its ability to bind FrMLV57, but showed very reduced binding
with Fr-gs1 (Fig. 5F). These data suggest that receptor polymorphism is
responsible for reduced infectivity of the gs1 mutants.
Discussion
Among the various factors responsible for intrinsic resistance to
retroviruses are several that inhibit virus entry. Such factors include
ERV produced Env glycoproteins that interfere with virus-receptor
binding, and mutations in receptor genes that alter their interactions
with viruses (Stocking and Kozak, 2008). For the MLVs, receptor
polymorphisms that recognize different Env variants have been
identiﬁed for the XPR1 receptor that mediates infection of xenotropic
and polytropic MLVs (XMVs and PMVs) (Marin et al., 1999; Yan et al.,
2007), viruses originally described as different host range groups
(Hartley et al., 1977). For the E-MLVs, there are fewer examples of
receptor-mediated host range variations, in part because, unlike the
X/PMVs that can infect all mammals tested, E-MLV infection is limited
to rodents. In addition, most known examples of E-MLV entry
restrictions are due, at least in part, to glycosylation of cellular
proteins. Because glycosylation of the viral Env has also been
associated with altered infectivity of multiple viruses including
MLVs (Battini et al., 1994) and other retroviruses (Ogert et al.,
2001), we examined the need for speciﬁc N-glycans in Env regions
important for entry. Here we show that deletion of speciﬁc N-glycan
sites from ecotropic MLV env genes produces viruses with altered host
range. This effect is receptor variant-speciﬁc, virus type-speciﬁc, and
glycan site-speciﬁc. Deletion of glycans gs1 and gs2 alters the host
range of MoMLV and FrMLV but not AKV MLV, and this restriction is
observed only in cells expressing two of the four naturally occurring
CAT-1 variants.
Virus infectivity was shown to be affected by glycan site deletion
but not by the alteration of glycan type or size. This suggests that the
role of glycans in host range may be a consequence of their
cotranslational placement on the Env protein, a process that may
result in conformational changes in the Env glycoprotein that
differentially alters recognition by the 4 receptor variants. Glycan
additions generally ensure proper folding of proteins, help maintain
their stability, and are needed for intracellular routing and further
processing. For MLV Env, blockage of glycosylation by tunicamycin
halts processing and translocation to the plasma membrane (Schultz
and Oroszlan, 1979). That glycan removal affects infectivity due to
altered folding rather than a speciﬁc role for glycans in entry is
consistent with the crystal structure of FrMLV (Fass et al., 1997) which
shows that neither gs1 nor gs2 is positioned near the residues in VRA
that form the pocket for virus binding, namely residues S84, D86 and
W102 (Davey et al., 1999).
Deletion of either of the 2 RBD glycan sites of MoMLV and gs1 of
FrMLV produces viruses that identify a functional distinction among
the 4 naturally occurring CAT-1 variants. These mutated viruses are
much less able to infect dunni and hamster cells, while infectivity on
rat XC cells and NIH 3T3 cells is not altered. These infectivity
differences are also seen in MA139 ferret cells expressing the dCAT-
1 and mCAT-1 receptor variants indicating that receptor polymorph-ism is the major responsible host cell factor. Virus binding assays
further demonstrate there is an association between infectivity and
the binding ability of Fr-gs1 compared to the wild type FrMLV in M.
dunni cells as well as in the transfected ferret cells. Infectivity can be,
however, affected by other, secondary cellular factors as shown by the
fact that glycosylation inhibitors can reduce this entry restriction inM.
dunni cells.
The three viruses used here have ecotropic host range, but show
signiﬁcant sequence variation in their RBDs and also differ in their
patterns of glycosylation (Fig. 1A). FrMLV and MoMLV are laboratory
isolates that, unlike AKV, are oncogenic in mice. Both viruses were
isolated after serial passage of tumors in mice and neither of these
viruses have counterparts that are found naturally in laboratory mice
or wild mouse species. In contrast, AKV MLVs are naturally occurring
MLVs carried as endogenous retroviruses by many inbred laboratory
strains and are also found in Asian species of Mus (Kozak and O'Neill,
1987). Sequence comparisons of their Env genes indicate closer
relationship between FrMLV and MoMLV (88% amino acid identity in
RBD) than between either of these viruses and AKV (78% identify).
These similarities are reﬂected in our results; removal of RBD glycan
sites from FrMLV and MoMLV similarly compromises infectivity in
cells expressing dCAT-1, whereas AKV mutants show no changes in
infectivity. Examination of other MLV isolates indicates there is
naturally occurring polymorphism at 4 glycan sites (gs3, 5, 7, and 8)
among ecotropic viruses suggesting that these sites are not critical for
producing infectious virus as shown here for gs8.
Mutational changes in the retroviral RBD can lead to the generation
of viruses that can use alternative receptors, multiple receptors or
even multiple determinants on the same receptor protein (Stocking
and Kozak, 2008). The coevolution of Env and receptor has resulted in
their sequence diversity and functional plasticity, and previous studies
have identiﬁed sequence variations in E-MLVs responsible for
variations in receptor usage (Yan et al., 2008; Masuda et al., 1996).
Such variants show altered infectivity into different mouse or hamster
cells, and differential ability to induce multinucleated syncytia. The
present study indicates that RBD glycans also serve to control virus
host range variation, a control that likely depends on protein folding
rather than a direct role in receptor interaction.
Methods
Viruses and cells
Two ecotropic MLV isolates were obtained from J. W. Hartley
(NIAID, Bethesda, MD): AKV MLV and Moloney MLV (MoMLV). We
also produced stocks of Friend and MoMLV from molecular clones of
FrMLV57 and MoMLV (pNCA-HA) obtained from S. Ruscetti (NCI,
Frederick, MD) (Oliff et al., 1980) and J. Silver (NIAID, Bethesda, MD)
(Ou et al., 2006).
Virus stocks were made by collecting culture ﬂuids from infected
or transfected cells. Infectious virus in these stocks was quantitated by
the XC overlay test (Rowe et al., 1970; Yan et al., 2008) following
infection of NIH 3T3 and 2 lines derived from tail cells of a single M.
terricolor (M. dunni) mouse; the two cell lines are here designated M.
dunni and MDTF (Lander and Chattopadhyay, 1984). The XC overlay
test was also used to assess virus susceptibility on Chinese hamster
E36 (Gillin et al., 1972) and Lec8 cells (ATCC CRL-1737), XC rat cells,
and MA139 ferret or M. dunni cells stably transfected with 3 CAT-1
receptor variants: mCAT-1 from NIH 3T3, dCAT-1 from M. dunni, and
dCAT-1-g, a variant of dCAT-1 from which both glycosylation sites
were removed by mutagenesis (Yan et al., 2008). Western analysis
indicates equivalent expression of mCAT-1 and dCAT-1 in the ferret
transfectants (Yan et al., 2008).
Subconﬂuent cultures were infected with appropriate dilutions of
virus stocks in the presence of polybrene (4 μg/ml; Aldrich,
Milwaukee, WI). The cells were irradiated 4 days after virus infection
Table 3
Primers used to generate MLVs lacking speciﬁc glycosylation sites.
Mutant Mutagenic primera Flanking primera
Mo-gs1 (N45Q) 5′-CAGTCCTCATCAAGTCTATcAgATCACCTGGGAGGTAACC (5890–5929) 5′-ATCGCAGCTTGGATACACGC (5706–5725)
5′-GGTTACCTCCCAGGTGATcTgATAGACTTGATGAGGACTG (5890–5929) 5′-AGTGGTAAGGTTCAGTATGG (7068–7087)
Mo-gs2 (N199D) 5′-ATTTCATCACAGTAAACAACgATCTCACCTCTGACCAGGC (6351–6390) 5′-ATCGCAGCTTGGATACACGC (5706–5725)
5′-GCCTGGTCAGAGGTGAGATcGTTGTTTACTGTGATGAAAT (6351–6390) 5′-AGTGGTAAGGTTCAGTATGG (7068–7087)
Mo-gs8 (N434Q) 5′-CATCTCCACCACCATACTGcAgCTTACCACTGATTATTGTG (7057–7097) 5′-ATCGCAGCTTGGATACACGC (5706–5725)
5′-CACAATAATCAGTGGTAAGcTgCAGTATGGTGGTGGAGATG (7057–7097) 5′-TGAGTGGCCATTAGAGCAGTAG (7263–7284)
AK-gs1 (N43Q) 5′-GCCCCCACCAGGTTTTTcAgCTCACCTGGGAAGTGAC (5892–5928) 5′-GACTGACTCCGTATGAAATC (5407–5426)
5′-GTCACTTCCCAGGTGAGcTgAAAAACCTGGTGGGGGC (5892–5928) 5′-TGGGGCAGAAGTATGGTT (6857–6874)
AK-gs2 (N199Q) 5′-CATCACAGTAAGCAACcAgCTAACCTCAGACCAGGCAACC (6361–6400) 5′-GACTGACTCCGTATGAAATC (5407–5426)
5′-GGTTGCCTGGTCTGAGGTTAGcTgGTTGCTTACTGTGATG (6361–6400) 5′-TGGGGCAGAAGTATGGTT (6857–6874)
Fr-gs1 (N46Q) 5′-GCCCTCACCAGGTCTACcAgATTACCTGGGAAGTGA (5896–5931) 5′-GCACCCCCGCCCCTTGTAA (5422–5440)
5′-TCACTTCCCAGGTAATcTgGTAGACCTGGTGAGGGC (5896–5931) 5′-CATGGAGCTGCTGGAACTGC (7316–7335)
a Lowercase letters represent introduced base substitutions. Numbers in parentheses indicate the positions in sequences from GenBank accession nos.: J02255 for Mo-gs1, Mo-gs2
and Mo-gs8; J01998 for AK-gs1 and AK-gs2; X02794 for Fr-gs1.
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and were then overlaid with XC cells. XC cells produce plaques of
multicleated syncytia in response to focal areas of virus-infected cells.
Cultures were ﬁxed and stained 3 days later and examined for plaques
of syncytia. Virus spread was poor in infected XC and Lec8 cells
making XC plaques difﬁcult to read, so infected cells were ﬁrst
irradiated and overlaid with NIH 3T3 or H3T3-1, a line derived in this
laboratory from tail cells ofM. spicilegus; these cells do not restrict any
ecotropic MLVs. After 3 days, cells were again irradiated and overlaid
with XC cells.
Inhibitors of N-linked glycosylation
Cells were treated by various inhibitors of N-linked glycosylation
as follows: deoxymannojirimycin (DMM, 100 μg/ml); castanosper-
mine (CST, 100 μg/ml), tunicamycin (Tu, 0.2 μg/ml); 2-deoxy-D-
glucose (2DG, 25 mM) deoxynojirimycin (DNM, 200 μg/ml);
swainsonine (Sw, 200 μg/ml). All inhibitors were obtained from
SIGMA (La Jolla, CA). Inhibitors were added to cultures that had been
seeded the previous day and were not removed when virus and
polybrene were added 18–24 h later. Cells were lysed for Western
immunoblotting 3–4 days later or were irradiated for the XC overlay
test. To generate viruses with altered N-glycans, inhibitors were added
to virus producing cells. Mediumwas replaced the next day and fresh
inhibitor was added. Virus was collected 3–4 days later.
Pseudotype assay
MoMLV, FrMLV57 and their respective gs1 mutants were used to
infect an NIH 3T3 derived cell line stably transfected with pCLMFG-
LacZ (Imgenex Co., San Diego, Calif.) and kindly provided by Dr. J.
Silver (NIAID, Bethesda, MD). Filtered media from the virus-infected
cultures contained amixture of infectious virus and LacZ pseudotypes.
Cells were infected with appropriate dilutions of these pseudotype
virus stocks in the presence of 4–8 μg/ml polybrene. One day after
infection, cells were ﬁxed with 0.4% glutaraldehyde and assayed for β-
galactosidase activity using as substrate 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (X-Gal, 2 mg/ml; ICN Biomedicals, Aurora,
Ohio). Infectious titers were expressed as the number of blue cells per
100 μl of virus supernatant.
Mutagenesis of MoMLV, AKV and FrMLV
Six mutant viruses lacking glycosylation sites gs1, gs2, or gs8 (Fig.
1A) were produced by overlapping PCR using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA). MoMLV mutants
Mo-gs1, Mo-gs2 and Mo-gs8 were generated using clone pNCA-HA
(obtained from J. Silver, NIAID, Bethesda, MD) (Ou et al., 2006). AKV
MLV mutants AK-gs1 and AK-gs2 were made using clone pGEM-AKV,containing the PstI fragment of AKV MLV from pAKV23 (obtained
from J. Lenz, Albert Einstein College of Medicine, Bronx, NY). FrMLV
mutant Fr-gs1 was produced using the FrMLV57 clone (obtained from
S. Ruscetti, NCI, Frederick, MD) (Oliff et al., 1980).
For each mutagenesis, sense and antisense primers containing the
various mutations were used in PCR reactions with ﬂanking 5′ and 3′
primers as indicated in Table 3. The two products of these reactions
were combined and used as template for a second PCR using the
ﬂanking primers. MoMLV PCR products lacking gs1 or gs2 were
digested with PmlI and NsiI and ligated into pNCA-HA; the MoMLV
fragment lacking gs8 was introduced as an HpaI fragment. The Fr-gs1
mutant was introduced into FrMLV57 as a SacII insertion. The AK-gs1
and AK-gs2 mutants were generated as follows: a 2.7 kb BsmI
fragment was recovered from pGEM-AKV using forward primer: 5′-
GCAGGAGTGAGAGTACGAGGACAT and reverse primer 5′-TGGAC-
CAGGCGATTGAGAA and cloned it into the vector pCR2.1-TOPO.
Overlapping PCR was performed using indicated primers and the
BsgI/AvrII fragments of the PCR product were cloned into the AKV
subclone. Two 2.7 kb BsmI fragments from these subclones containing
N43Q and N199Q were ligated into pGEM-AKV. All mutations were
conﬁrmed by sequencing; all clones of AK-gs1 and AK-gs2 contained
the additional mutation Q341H. Clones were transfected into NIH 3T3
cells and culture medium containing virus was collected.
Western immunoblotting
Lysates from virus-infected cells were tested for viral Env by
western immunoblot analysis. Cell lysates were subjected to electro-
phoresis on NuPAGE 4–12% Bis–Tris gels (Invitrogen, Carlsbad, CA).
Western blots were probed with two antibodies against MLV Env: a
goat polyclonal anti-Rauscher MLV gp70 antiserum (ViroMed Biosaf-
ety Laboratories, Camden, NJ) with peroxidase-conjugated rabbit anti-
goat IgG as the secondary antibody (Invitrogen, Eugene, OR), and
MAb538, a monoclonal anti-MoMLV antibody (Lander et al., 1999)
provided by J. Portis (NIAID, Hamilton, MT) with peroxidase-
conjugated goat anti-mouse IgG (Invitrogen).
Virus binding assay
The virus binding assay was performed essentially as described
previously (Kadan et al., 1992)]. NIH 3T3, M. dunni, MDTF and
transfected ferret cells were detached from culture ﬂasks by a short
treatment at room temperature with trypsin-EDTA (Gibco, Grand
Island, NY). Theywerewashed once and resuspended at 2million cells
per ml. One million cells were incubated in presence of 100 μl of virus
suspension and 8 μg/ml polybrene for 40 min at 37 °C in a ﬁnal
volume of 1 ml. Cells treated similarly in the absence of virus stock
served as negative control. Samples were mixed every 10 min. At the
end of the incubation, cells were washed twice with wash buffer (PBS
239R.C. Knoper et al. / Virology 391 (2009) 232–239supplemented with 1% bovine serum albumin). Virions bound to the
cells were detected by staining the cells ﬁrst with the goat anti-gp70
antiserum (1:200) in 100 μl for 30 min at 4 °C. After two washes with
wash buffer, cells were incubated with Alexa Fluor 488 labeled donkey
anti-goat IgG (Invitrogen, Carlsbad, CA) (1:500) in 100 μl for 30 min at
4 °C. After two additional washes, cells were resuspended in 500 μl
PBS. To exclude dead cells from the analysis, the cell suspension was
incubated at room temperature for 10 min with 20 μl 7-AAD solution
(BD Via Probe, BD Biosciences, San Jose CA) before being analyzed by
ﬂow cytometry (FACScalibur, BD Biosciences Immunocytometry
Systems). Fluorescence data of a minimum of 50,000 cells were
recorded and analysis was performed on live cells (7-AAD negative
cells, N90% of the population) using Cell Quest Pro (BD Biosciences).
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